Table 5 Estimates of key quantities characterizing the performance of the proposed two test workflow when 1-year or 3-year occurrences of hazardous events (HE) and clinical restenosis are taken into account
Estimated quantity | 1- year | 3- years | ||
|---|---|---|---|---|
Mean | 95% CI | Mean | 95% CI | |
\( \widehat{P}\left(\mathrm{sBMS}\right) \) | 5.6 | 3.4 – 9.8 | 6.4 | 3.1 – 13.0 |
\( \widehat{P}\left(\mathrm{sDES}\right) \) | 85.5 | 81.9 – 87.6 | 84.1 | 78.4 – 87.2 |
\( \widehat{P}\left(\mathrm{sCABG}\right) \) | 8.9 | 8.2 – 9.2 | 9.5 | 8.5 – 10.4 |
\( \widehat{P}\left(\mathrm{Restenosis}\left|\mathrm{sBMS}\right.\right) \) | 0.0 | 0.0 – 0.0 | 0.0 | 0.0 – 0.0 |
\( \tilde{P}\left(\mathrm{Restenosis}\left|\mathrm{sDES}\right.\right) \) | 2.9 | 1.9 – 3.4 | 8.2 | 7.6 – 9.0 |
\( \widehat{P}\left(\mathrm{Restenosis}\right) \) | 2.7 | 1.8 – 3.1 | 7.1 | 6.4 – 7.9 |
\( \tilde{P}\left(\mathrm{Hazard}\left|\mathrm{sBMS}\right.\right) \) | 7.2 | 0.0 – 16.1 | 9.9 | 0.0 – 21.4 |
\( \widehat{P}\left(\mathrm{Hazard}\left|\mathrm{sDES}\right.\right) \) | 3.2 | 2.0 – 3.5 | 7.4 | 5.6 – 8.9 |
\( \widehat{P}\left(\mathrm{Hazard}\right) \) | 3.9 | 2.7 – 4.6 | 7.6 | 6.2 – 8.9 |
Baseline estimate for P(Adverse effect) | 9.7 | 8.4 – 10.3 | 19.7 | 18.2 – 20.7 |
Proposed estimate for P(Adverse effect) | 6.5 | 5.0 – 7.6 | 14.7 | 13.1 – 16.1 |
ΔP(Adverse effect) | 3.2 | 2.7 – 3.8 | 4.9 | 4.1 – 6.2 |